Neilson KM, Friesel R. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellula transmembrane, and kinase domains. J Biol Chem. Oct. 4, 1996; 271(40):25049-57.* |
Mohammadi et al., Science, 276 (5314), 955-960 (May 9, 1997). |
Buchdunger et al., “4,5-bis (4-flouronilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivoantitumor activity,” Clin. Cancer Res., 1 (8), 813-821, (1995). |
Ciardello et al., “Cooperative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells,” Clin. Cancer. Res., 1 ( 2), 161-167 (1995). |
Coll-Fresno et al., “Cytotoxic activity of a diphteria toxin/FGF6 mitotoxin on human tumour cell lines,” Oncogene, 14 (2), 243-247 (1997). |
Dinney et al., “Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide,” Clin. Cancer Res., 3 (2), 161-168 (1997). |
Han et al., “Preferential inhibition of glioblastoma cell with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate,” Oncol. Res., 9 (11-12), 581-587 (1997). |
Normanno et al., “Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides,” Clin. Cancer Res., 2 (3), 601-609 (1996). |
Partanen et al., “FGFR-4, a novel acidic growth factor receptor with a distinct expression pattern,” EMBO J., 10 (6), 1347-1354 (1991). |
Rubin Grandis et al., “Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells,” Oncogene, 15 (4), 409-416 (1997). |
Showalter et al., “Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases,” Pharmacol. Ther., 76 (1-3), 55-61 (1997). |
Uehara , “Recent advances in development of antitumor tyrosine kinase inhibitors,” Gan To Kagaku, 24 (11), 1536-1540 (1997). |
CALBIOCHEM® Signal Transduction Catalog & Technical Resource, p. 259 (1998). |